WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H584374
CAS#: 131420-91-2
Description: E5090, a novel orally active inhibitor of IL-1 generation, has antiinflammatory properties.
Hodoodo Cat#: H584374
Name: E 5090
CAS#: 131420-91-2
Chemical Formula: C19H20O5
Exact Mass: 328.13
Molecular Weight: 328.364
Elemental Analysis: C, 69.50; H, 6.14; O, 24.36
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: E 5090; E5090; E-5090
IUPAC/Chemical Name: 2-Propenoic acid, 3-(4-(acetyloxy)-5-ethyl-3-methoxy-1-naphthalenyl)-2-methyl-, (Z)-
InChi Key: GMNKEZBZYKGPTL-LUAWRHEFSA-N
InChi Code: InChI=1S/C19H20O5/c1-5-13-7-6-8-15-14(9-11(2)19(21)22)10-16(23-4)18(17(13)15)24-12(3)20/h6-10H,5H2,1-4H3,(H,21,22)/b11-9-
SMILES Code: O=C(O)/C(C)=C\C1=C2C=CC=C(CC)C2=C(OC(C)=O)C(OC)=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 328.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Fukumura D, Miura S, Kurose I, Higuchi H, Suzuki H, Ebinuma H, Han JY, Watanabe N, Wakabayashi G, Kitajima M, Ishii H. IL-1 is an important mediator for microcirculatory changes in endotoxin-induced intestinal mucosal damage. Dig Dis Sci. 1996 Dec;41(12):2482-92. PubMed PMID: 9011462.
2: Tanaka M, Chiba K, Okita M, Kaneko T, Tagami K, Hibi S, Okamoto Y, Shirota H, Goto M, Obaishi H, et al. A novel orally active inhibitor of IL-1 generation: synthesis and structure-activity relationships of 3-(4-hydroxy-1-naphthalenyl)-2-propenoic acid derivatives. J Med Chem. 1992 Dec 11;35(25):4665-75. PubMed PMID: 1469696.
3: Chiba K, Goto M, Shirota H. A novel inhibitor of IL-1 generation, E5090: in vivo inhibitory effect on the generation of IL-1-like factor and on granuloma formation in an air-pouch model. Agents Actions Suppl. 1991;32:231-5. PubMed PMID: 2069092.
4: Goto M, Chiba K, Hashida R, Shirota H. A novel inhibitor of IL-1 generation, E5090: in vitro inhibitory effects on the generation of IL-1 by human monocytes. Agents Actions Suppl. 1991;32:225-9. PubMed PMID: 2069091.
5: Shirota H, Chiba K, Goto M, Hashida R, Ono H. Antiinflammatory properties of E5090, a novel orally active inhibitor of IL-1 generation. Agents Actions Suppl. 1991;32:219-23. PubMed PMID: 2069090.